Conferences - Results from #700

EAU 2024: Adjuvant Immunotherapy After pT3a F IV /N0 at Nephrectomy: Is That Real High-Risk for All? No April 8, 2024

EAU 2024: Does Scalpel Play a Role in Intermediate Risk Metastatic RCC? Upfront CN April 8, 2024

EAU 2024: State-of-the-Art Lecture: Staging High-Risk Prostate Cancer with PSMA PET: Strengths and Pitfalls April 8, 2024

EAU 2024: Efficacy of Transrectal and Transperineal Prostate Biopsy in Detecting Clinically Significant Prostate Cancer: Results of the ProBE-PC Randomised Clinical Trial April 8, 2024

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA + MRI + Targeted Biopsies Only (Gothenburg-2 Trial) April 8, 2024

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA + MRI (OPT - the Swedish Nationwide Screening Strategy) April 8, 2024

EAU 2024: Synchronous mHSPC: What Are the Treatment Options and What Are the Goals of Treatment? What Is the Evidence for Radiotherapy April 8, 2024

EAU 2024: PARP-Inhibitors Only for Patients with Alterations in DNA Repair Genes: No April 8, 2024

EAU 2024: Urological Follow-up of Lynch Syndrome: Upper Tract Urothelial Carcinoma Incidence and Mutational Patterns in a Dedicated Outpatient Clinic April 8, 2024

EAU 2024: Photodynamic Diagnosis (PDD) Directed Biopsies vs White Light Bladder Mapping in Patients with Positive Cytology and Negative Preoperative Workup: An International Multicenter Retrospective Study April 8, 2024

EAU 2024: First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab Nab-Paclitaxel Followed by Postsurgical Adjuvant Nivolumab in Patients with Muscle-Invasive Bladder Cancer April 8, 2024

European Association of Urology (EAU) 2024 Congress Features New Data on Modern Technology Use in Bladder Cancer Care April 8, 2024

EAU 2024: Adjuvant Immunotherapy After pT3a F IV /N0 at Nephrectomy: Is That Real High-Risk for All? Yes April 8, 2024

EAU 2024: PARP-Inhibitors Only for Patients with Alterations in DNA Repair Genes: The Guidelines' View April 8, 2024

EAU 2024: PARP-Inhibitors Only for Patients with Alterations in DNA Repair Genes: Yes April 8, 2024

EAU 2024: Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through 18F-DCFPyL-PSMA-PET/CT Scans in Pre-Treatment Prostate Cancer Patients April 8, 2024

EAU 2024: State-of-the-Art Lecture: Advancements in Cutting-Edge SBRT Therapy for Oligometastatic Kidney Cancer April 8, 2024

EAU 2024: A Prospective, Comparative, Within-Patient Controlled Multicenter Phase III Study Comparing Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer Using Modern HD 4K Equipment April 8, 2024

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA + Risk Calculators + MRI (The EAU Screening Algorithm) April 8, 2024

EAU 2024: Non-Thermal Atmospheric Plasma Ablation for Intermediate Risk Non-Muscle Invasive Bladder Cancer: A First in Human Trial April 7, 2024

Page 36 of 588